Acipimox

Research use only, not for human use.

Acipimox is a niacin derivative used as a hypolipidemic agent.

Acipimox is a niacin derivative used as a hypolipidemic agent. It is used in low doses and may have less marked adverse effects, although it is unclear whether the recommended dose is as effective as are standard doses of nicotinic acid. Acipimox inhibits the production of triglycerides by the liver and the secretion of VLDL, which leads indirectly to a modest reduction in LDL and increase in HDL. Long-term administration is associated with reduced mortality, but unwanted effects limit its clinical use. (In Vitro):Acipimox (0-100 μM; 0-4 hours) enhances leptin release from adipocytes isolated from Sprague-Dawley rats in a time- and dose- dependent manner.Acipimox (10 mM) stimulats leptin release in adipocytes from Streptozotocin (STZ)-treated and Zucker diabetic fat (ZDF) rats.(In Vivo):Acipimox (50 mg/kg; i.p.) significantly lowers circulating free fatty acid (FFA) and glucose in high-fat fed mice.

Acipimox (0-100 μM; 0-4 hours) enhances leptin release from adipocytes isolated from Sprague-Dawley rats in a time- and dose- dependent manner.Acipimox (10 mM) stimulats leptin release in adipocytes from Streptozotocin (STZ)-treated and Zucker diabetic fat (ZDF) rats.

Acipimox (50 mg/kg; i.p.) significantly lowers circulating free fatty acid (FFA) and glucose in high-fat fed mice. Animal Model:Female C57BL/6J mice Dosage:50 mg/kg Administration:Intraperitoneal injection Result:Reduced circulating levels of FFA and glucose after 3 h.

Acipimox | K-9321 | K9321 | K 9321 | Olbemox | Olbetam

Others

Other Targets

triglycerides production

Cardiovascular Disease

——

51037-30-0

154.13

C6H6N2O3

>98% (HPLC)

DMSO: 31 mg/mL (201.14 mM)

O=C(C1=C[N+]([O-])=C(C)C=N1)O

5-carboxy-2-methylpyrazine 1-oxide

(-20℃)

With Ice Pack

≥ 2 years